Skip to main
NBIX
NBIX logo

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences (NBIX) Analyst Ratings

Based on 33 analyst ratings
Buy
Strong Buy 39%
Buy 42%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Neurocrine Biosciences Inc. is poised for significant growth driven by the increasing patient population for congenital adrenal hyperplasia, with a noted rise of 3,000 patients since 2018, highlighting unmet medical needs in this area. The company's management remains optimistic about the long-term potential of Ingrezza, particularly given that a majority of tardive dyskinesia patients are yet to be treated with VMAT2 inhibitors and the expanding use of antipsychotics is expected to boost demand. Furthermore, the upcoming pivotal clinical programs in major depressive disorder and schizophrenia, along with anticipated Phase II and III readouts, are likely to serve as pivotal catalysts for future growth.

Bears say

Neurocrine Biosciences faces a negative outlook primarily due to the company's lower-than-expected sales guidance for Ingrezza, projected at $2.5-2.6 billion for FY25, which falls short of consensus estimates and suggests a deceleration in revenue growth driven by increased competitive pressures and complex payer dynamics. Additionally, the 4Q24 sales of Ingrezza, reported at approximately $615 million, were marginally below both consensus and internal forecasts, indicating stagnation in quarter-over-quarter growth. The revised total revenue assumption for the end of 2025 has been decreased from $2,846 million to $2,648 million, further underscoring the challenges the company is facing in achieving its financial targets.

Neurocrine Biosciences (NBIX) has been analyzed by 33 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 42% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurocrine Biosciences (NBIX) Forecast

Analysts have given Neurocrine Biosciences (NBIX) a Buy based on their latest research and market trends.

According to 33 analysts, Neurocrine Biosciences (NBIX) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurocrine Biosciences (NBIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.